An important research project testing the targeted capabilities of our antimicrobial platform, conducted in collaboration with The University of Queensland, has been published in Communications Biology – a leading peer-reviewed journal by Nature Research.
The research article titled “The antimicrobial potential of cannabidiol” reveals the unique mechanism through which synthetic cannabidiol can kill the bacteria responsible for gonorrhoea, meningitis and legionnaires disease – a world first.
All research data generated is fully-owned by Botanix and the subject of several patent applications,and it culminates significant collaborations involving respected antimicrobial researchers from around the world. The lead author is Dr Mark Blaskovich, Director of the University of Queensland’s Centre for Superbug Solutions in the Institute for Molecular Science, and it is co-authored by Botanix Directors Matt Callahan and Dr Michael Thurn.
This is truly exciting for our antimicrobial platform. This new data demonstrates our potential to develop novel structural analogs of cannabinoids with increased antimicrobial activity providing a foundation for the development of a whole new class of antimicrobials.
The news comes as we are finalising data for our BTX 1801 Phase 2a clinical study out of Perth. We are proud to be leading a promising new chapter of evidence-based research and action to address antimicrobial resistance – a pressing priority for the largest health agencies in the world.